Market Overview

UPDATE: Goldman Sachs Raises PT to $6.60 on Boston Scientific Following Q4 Takeaways

Share:
Related BSX
A Peek Into The Markets: U.S. Stock Futures Mostly Flat; Ford Earnings Miss Views
Boston Scientific Q2 Revenue Beats Guidance, Fueled By Deep Portfolio
Boston Scientific (BSX) Michael F. Mahoney on Q2 2016 Results - Earnings Call Transcript (Seeking Alpha)

Goldman Sachs maintained Boston Scientific Corporation (NYSE: BSX) with a Sell rating and raised the price target from $5.20 to $6.60.

Goldman Sachs noted, "Following 4Q12 results, we adjust our 2013-2016E EPS to reflect: (1) increased sales across most businesses, aside from CRM; (2) revised gross margin assumptions; (3) higher operating expenses; (4) higher interest expense; and (5) increased share repurchases. Still, our revised 2013 sales estimate is now at the low end of guidance (-1.6% vs. the guidance midpoint at -0.7%), as we remain cautious on Boston's business exposure and relative share position."

Boston Scientific closed at $7.10 on Tuesday.

Latest Ratings for BSX

DateFirmActionFromTo
Jun 2016Guggenheim SecuritiesInitiates Coverage onBuy
May 2016BTIG ResearchDowngradesBuyNeutral
Mar 2016NomuraInitiates Coverage onBuy

View More Analyst Ratings for BSX
View the Latest Analyst Ratings

Posted-In: Goldman SachsAnalyst Color Price Target Analyst Ratings

 

Related Articles (BSX)

View Comments and Join the Discussion!